Enter assignee name

% Expired Patents = 14.3

EPO Patents = 10

Trademarks = 1

Forward Citations = 20

Loading Chart...

1 inventor (with patents filed for the assignee):

Daewoong Jo (14 out of 14 patents)

Chang Su Lee (2 patents)

Jun Hyeong Choi (0 patent)

14 patents: Sort by Forward Citations

1. 11319546 - Cell-permeable (CP)-Cas9 recombinant protein and uses thereof (2022-05-03),

2. 11279743 - Cell-permeable bone morphogenetic protein (CPBMP) recombinant protein and use thereof (2022-03-22),

3. 10975132 - Cell-permeable (ICP)-SOCS3 recombinant protein and uses thereof (2021-04-13),

4. 10961292 - Cell-permeable (ICP)-SOCS3 recombinant protein and uses thereof (2021-03-30),

5. 10787492 - Cell-permeable (iCP)-SOCS3 recombinant protein and uses thereof (2020-09-29),

6. 10781241 - Cell-permeable (iCP)-SOCS3 recombinant protein and uses thereof (2020-09-22),

7. 10774123 - Cell-permeable bone morphogenetic protein (CP-BMP) recombinant protein and use thereof (2020-09-15),

8. 10689424 - Cell-permeable (CP)-Δ SOCS3 recombinant protein and uses thereof (2020-06-23),

9. 10669531 - Cell-permeable Cre (iCP-Cre) recombinant protein and use thereof (2020-06-02),

10. 10662419 - Cell-permeable (ICP) parkin recombinant protein and use thereof (2020-05-26),

11. 10508265 - Cell-permeable reprogramming factor (iCP-RF) recombinant protein and use thereof (2019-12-17),

12. 10385103 - Cell-permeable (ICP)-SOCS3 recombinant protein and uses thereof (2019-08-20),

13. 10323072 - Cell-permeable (CP)-Δ SOCS3 recombinant protein and uses thereof (2019-06-18),

14. 10323063 - Advanced macromolecule transduction domain (aMTD) sequences for improvement of cell-permeability, polynucleotides encoding the same, method to identify the unique features of aMTDs comprising the same, method to develop the aMTD sequences comprising the same (2019-06-18),

CELLIVERY THERAPEUTICS, INC. is a biotechnology company focused on developing personalized cell therapies for the treatment of cancer. They utilize innovative cell engineering and delivery technologies to create targeted treatments that harness the patient's own immune system to fight cancer cells. With a mission to improve patient outcomes and revolutionize cancer therapy, CELLIVERY THERAPEUTICS is at the forefront of cutting-edge research and development in the field of oncology.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

14 Patents

#294 in Seoul

#820 in South Korea

#42,168 in the World

Seoul, South Korea

Cellivery Therapeutics, Inc.

Forward Citations = 20

1 inventor:

Daewoong Jo (14 out of 14 patents)

Chang Su Lee (2 patents)

Jun Hyeong Choi (0 patent)

Please report any incorrect information to [email protected]